Previous 10 | Next 10 |
Yoshiharu Global Co. (YOSH) is expected to report for Q1 2024 Analog Devices Inc. (ADI) is expected to report $1.26 for Q2 2024 Simplicity Esports (WINR) is expected to report for Q3 2024 Klepierre (KLPEF) is expected to report for Q1 2024 Synopsys Inc. (SNPS) is expected to repor...
BioLineRx to Report First Quarter 2024 Results on May 28, 2024 PR Newswire Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , May 22, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceut...
2024-05-17 17:07:22 ET More on biolinerx Seeking Alpha’s Quant Rating on biolinerx Historical earnings data for biolinerx Financial information for biolinerx Read the full article on Seeking Alpha For further details see: BioLineRx receives...
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024 PR Newswire - Presentation Today, Monday, May 6, 2024 in Atlanta , Geo...
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting PR Newswire TEL AVIV, Israel , April 17, 2024 /PRNewswire/ --...
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement PR Newswire - Proceeds to be used to further accelerate uptake of APHEXDA® in stem cell mobilization, life-cycle expansion activities in sic...
2024-04-01 09:14:30 ET More on biolinerx Seeking Alpha’s Quant Rating on biolinerx Financial information for biolinerx Read the full article on Seeking Alpha For further details see: BioLineRx to raise $6M through a direct offering
BioLineRx Announces $6 Million Registered Direct Offering PR Newswire TEL AVIV, Israel , April 1, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing t...
2024-03-26 11:53:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioLine Rx (NASDAQ: BLRX ) just reported results for the fourth quarter of 2023. BioLine Rx reported earnings per share of -15 cents. This was above the analyst estimate f...
2024-03-26 11:38:10 ET BioLineRx Ltd. (BLRX) Q4 2023 Earnings Conference Call March 26, 2024 08:30 AM ET Company Participants John Lacey - Head of IR & Corporate Communications Phil Serlin - CEO Holly May - President of BioLineRx USA Mali Zeevi - CFO ...
News, Short Squeeze, Breakout and More Instantly...
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) PR Newswire - Investigator-initiated study in...
Orkla ASA ADR (ORKLY) is expected to report for Q1 2024 Cosmos Health Inc. (COSM) is expected to report $-0.14 for Q1 2024 Basilea Pharmaceutica AG Registered Shares (BPMUF) is expected to report for Q1 2024 DCC Plc (DCCPF) is expected to report for Q4 2024 Datatec Ltd ADR (DTTLY)...
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting PR Newswire New analysis of biopsy samples demonstrate...